APO Research
Talk to an analyst

APO RESEARCH · REPORT

Irritable Bowel Syndrome Treatment Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Irritable Bowel Syndrome Treatment Drug Market Outlook and Growth Opportunities 2026

21 December 2025195 pages

Choose your research edition.

Industry ResearchIrritable Bowel Syndrome Treatment Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Irritable Bowel Syndrome Treatment Drug Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Irritable Bowel Syndrome Treatment Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Irritable Bowel Syndrome Treatment Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Irritable Bowel Syndrome Treatment Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Irritable Bowel Syndrome Treatment Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Irritable Bowel Syndrome Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Irritable Bowel Syndrome Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Irritable Bowel Syndrome Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Irritable Bowel Syndrome Treatment Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Irritable Bowel Syndrome Treatment Drug market include Takeda Pharmaceutical Ltd, Johnson & Johnson, Roche, Pfizer Inc., Biogen, Abbvie Inc., AstraZeneca, Prometheus Laboratories Inc. (Nestle) and Bristol Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Irritable Bowel Syndrome Treatment Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Irritable Bowel Syndrome Treatment Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Irritable Bowel Syndrome Treatment Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Irritable Bowel Syndrome Treatment Drug market.

Irritable Bowel Syndrome Treatment Drug Segment by Company

Takeda Pharmaceutical Ltd

Johnson & Johnson

Roche

Pfizer Inc.

Biogen

Abbvie Inc.

AstraZeneca

Prometheus Laboratories Inc. (Nestle)

Bristol Myers Squibb

Bausch Health

Irritable Bowel Syndrome Treatment Drug Segment by Type

Corticosteroids

Immunomodulators

Antibiotics

Amino Salicylates

Others

Irritable Bowel Syndrome Treatment Drug Segment by Application

Hospitals

Specialty Clinics

Other

Irritable Bowel Syndrome Treatment Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Irritable Bowel Syndrome Treatment Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Irritable Bowel Syndrome Treatment Drug key companies, revenue, market share, and recent developments.

3. To split the Irritable Bowel Syndrome Treatment Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Irritable Bowel Syndrome Treatment Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Irritable Bowel Syndrome Treatment Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Irritable Bowel Syndrome Treatment Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome Treatment Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Irritable Bowel Syndrome Treatment Drug industry.

Chapter 3: Detailed analysis of Irritable Bowel Syndrome Treatment Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Irritable Bowel Syndrome Treatment Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Irritable Bowel Syndrome Treatment Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Irritable Bowel Syndrome Treatment Drug Industry Trends Table 2. Irritable Bowel Syndrome Treatment Drug Industry Drivers Table 3. Irritable Bowel Syndrome Treatment Drug Industry Opportunities and Challenges Table 4. Irritable Bowel Syndrome Treatment Drug Industry Restraints Table 5. Global Irritable Bowel Syndrome Treatment Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Irritable Bowel Syndrome Treatment Drug Revenue Share by Company (2021-2026) Table 7. Global Irritable Bowel Syndrome Treatment Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Irritable Bowel Syndrome Treatment Drug Key Company Manufacturing Base & Headquarters Table 9. Global Irritable Bowel Syndrome Treatment Drug Company, Product Type & Application Table 10. Global Irritable Bowel Syndrome Treatment Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Irritable Bowel Syndrome Treatment Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Corticosteroids Table 15. Significant Companies of Immunomodulators Table 16. Significant Companies of Antibiotics Table 17. Significant Companies of Amino Salicylates Table 18. Significant Companies of Others Table 19. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type (2021-2026) Table 23. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Specialty Clinics Table 26. Significant Companies of Other Table 27. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application (2021-2026) Table 31. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application (2027-2032) Table 32. Global Irritable Bowel Syndrome Treatment Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Region (2021-2026) Table 35. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Region (2027-2032) Table 37. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Irritable Bowel Syndrome Treatment Drug Sales Value Market Share by Country (2021-2026) Table 40. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Irritable Bowel Syndrome Treatment Drug Sales Value Market Share by Country (2027-2032) Table 42. Takeda Pharmaceutical Ltd Company Information Table 43. Takeda Pharmaceutical Ltd Business Overview Table 44. Takeda Pharmaceutical Ltd Irritable Bowel Syndrome Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Takeda Pharmaceutical Ltd Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 46. Takeda Pharmaceutical Ltd Recent Development Table 47. Johnson & Johnson Company Information Table 48. Johnson & Johnson Business Overview Table 49. Johnson & Johnson Irritable Bowel Syndrome Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Johnson & Johnson Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 51. Johnson & Johnson Recent Development Table 52. Roche Company Information Table 53. Roche Business Overview Table 54. Roche Irritable Bowel Syndrome Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Roche Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 56. Roche Recent Development Table 57. Pfizer Inc. Company Information Table 58. Pfizer Inc. Business Overview Table 59. Pfizer Inc. Irritable Bowel Syndrome Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Pfizer Inc. Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 61. Pfizer Inc. Recent Development Table 62. Biogen Company Information Table 63. Biogen Business Overview Table 64. Biogen Irritable Bowel Syndrome Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Biogen Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 66. Biogen Recent Development Table 67. Abbvie Inc. Company Information Table 68. Abbvie Inc. Business Overview Table 69. Abbvie Inc. Irritable Bowel Syndrome Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Abbvie Inc. Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 71. Abbvie Inc. Recent Development Table 72. AstraZeneca Company Information Table 73. AstraZeneca Business Overview Table 74. AstraZeneca Irritable Bowel Syndrome Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. AstraZeneca Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 76. AstraZeneca Recent Development Table 77. Prometheus Laboratories Inc. (Nestle) Company Information Table 78. Prometheus Laboratories Inc. (Nestle) Business Overview Table 79. Prometheus Laboratories Inc. (Nestle) Irritable Bowel Syndrome Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Prometheus Laboratories Inc. (Nestle) Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 81. Prometheus Laboratories Inc. (Nestle) Recent Development Table 82. Bristol Myers Squibb Company Information Table 83. Bristol Myers Squibb Business Overview Table 84. Bristol Myers Squibb Irritable Bowel Syndrome Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Bristol Myers Squibb Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 86. Bristol Myers Squibb Recent Development Table 87. Bausch Health Company Information Table 88. Bausch Health Business Overview Table 89. Bausch Health Irritable Bowel Syndrome Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Bausch Health Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 91. Bausch Health Recent Development Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Irritable Bowel Syndrome Treatment Drug Product Image Figure 2. Global Irritable Bowel Syndrome Treatment Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Irritable Bowel Syndrome Treatment Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Irritable Bowel Syndrome Treatment Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Corticosteroids Image Figure 8. Immunomodulators Image Figure 9. Antibiotics Image Figure 10. Amino Salicylates Image Figure 11. Others Image Figure 12. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Specialty Clinics Image Figure 17. Other Image Figure 18. Global Irritable Bowel Syndrome Treatment Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application (2021-2032) Figure 21. Global Irritable Bowel Syndrome Treatment Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Irritable Bowel Syndrome Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 24. North America Irritable Bowel Syndrome Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Irritable Bowel Syndrome Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Irritable Bowel Syndrome Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Irritable Bowel Syndrome Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Irritable Bowel Syndrome Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Irritable Bowel Syndrome Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 30. South America Irritable Bowel Syndrome Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Irritable Bowel Syndrome Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Irritable Bowel Syndrome Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Corticosteroids
  • Immunomodulators
  • Antibiotics
  • Amino Salicylates
  • Others
Applications
  • Hospitals
  • Specialty Clinics
  • Other
Companies covered
  • Takeda Pharmaceutical Ltd
  • Johnson & Johnson
  • Roche
  • Pfizer Inc.
  • Biogen
  • Abbvie Inc.
  • AstraZeneca
  • Prometheus Laboratories Inc. (Nestle)
  • Bristol Myers Squibb
  • Bausch Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Irritable Bowel Syndrome Treatment Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Irritable Bowel Syndrome Treatment Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Irritable Bowel Syndrome Treatment Drug Market Dynamics
  1. 2.1 Irritable Bowel Syndrome Treatment Drug Industry Trends
  2. 2.2 Irritable Bowel Syndrome Treatment Drug Industry Drivers
  3. 2.3 Irritable Bowel Syndrome Treatment Drug Industry Opportunities and Challenges
  4. 2.4 Irritable Bowel Syndrome Treatment Drug Industry Restraints
3 Irritable Bowel Syndrome Treatment Drug Market by Company
  1. 3.1 Global Irritable Bowel Syndrome Treatment Drug Company Revenue Ranking in 2025
  2. 3.2 Global Irritable Bowel Syndrome Treatment Drug Revenue by Company (2021-2026)
  3. 3.3 Global Irritable Bowel Syndrome Treatment Drug Company Ranking (2024-2026)
  4. 3.4 Global Irritable Bowel Syndrome Treatment Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Irritable Bowel Syndrome Treatment Drug Company Product Type and Application
  6. 3.6 Global Irritable Bowel Syndrome Treatment Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Irritable Bowel Syndrome Treatment Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Irritable Bowel Syndrome Treatment Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Irritable Bowel Syndrome Treatment Drug Market by Type
  1. 4.1 Irritable Bowel Syndrome Treatment Drug Type Introduction
  2. 4.1.1 Corticosteroids
  3. 4.1.2 Immunomodulators
  4. 4.1.3 Antibiotics
  5. 4.1.4 Amino Salicylates
  6. 4.1.5 Others
  7. 4.2 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Type
  8. 4.2.1 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Type (2021-2032)
  10. 4.2.3 Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type (2021-2032)
5 Irritable Bowel Syndrome Treatment Drug Market by Application
  1. 5.1 Irritable Bowel Syndrome Treatment Drug Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Specialty Clinics
  4. 5.1.3 Other
  5. 5.2 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Application
  6. 5.2.1 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application (2021-2032)
6 Irritable Bowel Syndrome Treatment Drug Regional Value Analysis
  1. 6.1 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Irritable Bowel Syndrome Treatment Drug Sales Value (2021-2032)
  7. 6.3.2 North America Irritable Bowel Syndrome Treatment Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Irritable Bowel Syndrome Treatment Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Irritable Bowel Syndrome Treatment Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Irritable Bowel Syndrome Treatment Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Irritable Bowel Syndrome Treatment Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Irritable Bowel Syndrome Treatment Drug Sales Value (2021-2032)
  16. 6.6.2 South America Irritable Bowel Syndrome Treatment Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Irritable Bowel Syndrome Treatment Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Irritable Bowel Syndrome Treatment Drug Sales Value Share by Country, 2025 VS 2032
7 Irritable Bowel Syndrome Treatment Drug Country-level Value Analysis
  1. 7.1 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Irritable Bowel Syndrome Treatment Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Irritable Bowel Syndrome Treatment Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Irritable Bowel Syndrome Treatment Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Irritable Bowel Syndrome Treatment Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Ltd
  2. 8.1.1 Takeda Pharmaceutical Ltd Company Information
  3. 8.1.2 Takeda Pharmaceutical Ltd Business Overview
  4. 8.1.3 Takeda Pharmaceutical Ltd Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Ltd Irritable Bowel Syndrome Treatment Drug Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Ltd Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Irritable Bowel Syndrome Treatment Drug Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Irritable Bowel Syndrome Treatment Drug Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Pfizer Inc.
  20. 8.4.1 Pfizer Inc. Company Information
  21. 8.4.2 Pfizer Inc. Business Overview
  22. 8.4.3 Pfizer Inc. Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc. Irritable Bowel Syndrome Treatment Drug Product Portfolio
  24. 8.4.5 Pfizer Inc. Recent Developments
  25. 8.5 Biogen
  26. 8.5.1 Biogen Company Information
  27. 8.5.2 Biogen Business Overview
  28. 8.5.3 Biogen Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Biogen Irritable Bowel Syndrome Treatment Drug Product Portfolio
  30. 8.5.5 Biogen Recent Developments
  31. 8.6 Abbvie Inc.
  32. 8.6.1 Abbvie Inc. Company Information
  33. 8.6.2 Abbvie Inc. Business Overview
  34. 8.6.3 Abbvie Inc. Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Abbvie Inc. Irritable Bowel Syndrome Treatment Drug Product Portfolio
  36. 8.6.5 Abbvie Inc. Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Irritable Bowel Syndrome Treatment Drug Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Prometheus Laboratories Inc. (Nestle)
  44. 8.8.1 Prometheus Laboratories Inc. (Nestle) Company Information
  45. 8.8.2 Prometheus Laboratories Inc. (Nestle) Business Overview
  46. 8.8.3 Prometheus Laboratories Inc. (Nestle) Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Prometheus Laboratories Inc. (Nestle) Irritable Bowel Syndrome Treatment Drug Product Portfolio
  48. 8.8.5 Prometheus Laboratories Inc. (Nestle) Recent Developments
  49. 8.9 Bristol Myers Squibb
  50. 8.9.1 Bristol Myers Squibb Company Information
  51. 8.9.2 Bristol Myers Squibb Business Overview
  52. 8.9.3 Bristol Myers Squibb Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bristol Myers Squibb Irritable Bowel Syndrome Treatment Drug Product Portfolio
  54. 8.9.5 Bristol Myers Squibb Recent Developments
  55. 8.10 Bausch Health
  56. 8.10.1 Bausch Health Company Information
  57. 8.10.2 Bausch Health Business Overview
  58. 8.10.3 Bausch Health Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bausch Health Irritable Bowel Syndrome Treatment Drug Product Portfolio
  60. 8.10.5 Bausch Health Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst